Apellis Pharmaceuticals, Inc.APLSNASDAQ
Loading
Year-over-year debt growth rate
5Y CAGR
+12.1%/yr
Long-term compound
Percentile
P85
Within normal range
vs 5Y Ago
1.8x
Solid growth
Streak
5 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 2.30% |
| Q3 2025 | 1.19% |
| Q2 2025 | 0.05% |
| Q1 2025 | -0.05% |
| Q4 2024 | -0.14% |
| Q3 2024 | -0.86% |
| Q2 2024 | 146.27% |
| Q1 2024 | 73.70% |
| Q4 2023 | 1.23% |
| Q3 2023 | -1.11% |
| Q2 2023 | -0.96% |
| Q1 2023 | -0.75% |
| Q4 2022 | -0.58% |
| Q3 2022 | -46.35% |
| Q2 2022 | 0.42% |
| Q1 2022 | 0.09% |
| Q4 2021 | -0.76% |
| Q3 2021 | -48.29% |
| Q2 2021 | -0.08% |
| Q1 2021 | 8.53% |
| Q4 2020 | 1.30% |
| Q3 2020 | 2.94% |
| Q2 2020 | 128.27% |
| Q1 2020 | 1.05% |
| Q4 2019 | 1.85% |
| Q3 2019 | 1043.17% |
| Q2 2019 | 0.88% |
| Q1 2019 | -50.57% |
| Q4 2018 | 0.51% |
| Q3 2018 | 0.54% |
| Q2 2018 | 0.55% |
| Q1 2018 | 0.86% |
| Q4 2017 | 0.00% |
| Q3 2017 | 0.00% |
| Q2 2017 | 0.00% |
| Q1 2017 | 0.00% |
| Q4 2016 | 0.00% |
| Q3 2016 | 0.00% |
| Q2 2016 | 0.00% |
| Q1 2016 | 0.00% |